The resulting dispute between Lilly and FDA – i.e. whether retatrutide is a biological product or drug – is important not only for Lilly, but for the future of the GLP-1 industry.

Lilly announced on Thursday, Dec. 5 a $3 billion expansion of its Kenosha County manufacturing facility. Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...

Eli Lilly files lawsuit against Indianapolis-based weight loss company Eli Lilly and Company is filing a lawsuit against Premier Weight Loss, an Indianapolis-based med spa who Lilly says is misleading ...

In August, Eli Lilly began offering Zepbound vials in 2.5mg and 5mg dosage strengths through its online LillyDirect pharmacy at a discount of 50% or more compared to the list price of other GLP-1 ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug ...

Eli Lilly 's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial. The ...